They offer potential for gene editing and disease treatment, including the correction of RPE65 mutations and restoration of pigment expression in RPE cells, which appear to be possible strategies for LCA treatment 122 (Figure 14G). This evidence concerns the gene RPE65 and Leber congenital amaurosis.